Risk Analysis

Showing 7969 articles
Business

Novo Nordisk's CagriSema Shows Superior Efficacy in Phase 3 Diabetes Trial, Bolstering Pipeline and Valuation Outlook

Novo Nordisk's combination therapy CagriSema has outperformed semaglutide in a pivotal Phase 3 trial for type 2 diabetes, significantly reducing blood sugar and weight. The strong results set the stage for regulatory discussions and reinforce the company's dominance in the metabolic treatment arena, amid heightened investor focus on its long-term growth potential.